Comparison
Epitalon vs TUDCA
Side-by-side of Epitalon and TUDCA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
TUDCA
TUDCA is the taurine-conjugated form of ursodeoxycholic acid, a bile-acid molecule with replicated effects on liver function, ER stress, and bile flow.
Effects at a glance
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
TUDCA
- •Bile-acid molecule (taurine-conjugated UDCA) with chemical chaperone activity at the endoplasmic reticulum
- •Established pharmaceutical use for cholestasis and primary biliary cholangitis at 500-750 mg/day
- •Reduces ER stress and stabilizes misfolded proteins; the mechanistic basis for emerging ALS / retinal applications
- •Modest improvements in NAFLD markers and insulin sensitivity at 500-1,750 mg/day in small trials
- •Mitochondrial protection signal in animal models drives the longevity-supplement positioning
- •Generally well-tolerated; mild GI effects are the main dose-dependent issue
Side-by-side
| Attribute | Epitalon | TUDCA |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) | tauroursodeoxycholic acid, taurine-conjugated UDCA |
| Half-life (hr) ↗ | 0.5 | 4 |
| Typical dose (mg) ↗ | 5 | 500 |
| Dosing frequency | daily during cycle | daily, divided into 2 doses with food |
| Routes | subcutaneous, intramuscular, intranasal | oral |
| Onset (hr) | 24 | 1 |
| Peak (hr) | 168 | 2 |
| Molecular weight | 390.35 | 499.7 |
| Molecular formula | C14H22N4O9 | C26H45NO6S |
| Mechanism | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. | Bile-acid signaling via FXR/TGR5 receptors; chemical chaperone reducing ER stress and unfolded protein response; mitochondrial protection through reduced outer-membrane permeabilization. |
| Legal status | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU | OTC dietary supplement (US); pharmaceutical in Italy and several Asian countries |
| WADA status | unknown | allowed |
| DEA / Rx | Not scheduled (research chemical) | OTC supplement |
| Pregnancy | Insufficient data; not recommended | Insufficient data for supplement use; UDCA used in cholestasis of pregnancy |
| CAS | 307297-39-8 | 14605-22-2 |
| PubChem CID | 219042 | 9848818 |
| Wikidata | Q5384126 | Q418751 |
Safety profile
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
TUDCA
Common side effects
- mild GI upset
- diarrhea (dose-dependent)
- constipation (rare)
- nausea
Contraindications
- complete biliary obstruction
- pregnancy / lactation (insufficient supplement-dose data)
- active GI disease without medical supervision
Interactions
- cyclosporine, oral contraceptives, fat-soluble vitamins: modest absorption changes via altered bile-acid pool(minor)
- phenylbutyrate: synergistic for ALS use (Relyvrio combination); consult clinician(moderate)
Which Should You Take?
TUDCA comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
- → If your priority is circadian regulation, pick Epitalon.
- → If your priority is liver function, pick TUDCA.
- → If your priority is mitochondrial function, pick TUDCA.
Edge case: If you want to avoid research-only / gray-market sourcing, TUDCA is the more accessible choice.
Default choice: TUDCA. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Epitalon and TUDCA?
Epitalon and TUDCA differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Epitalon or TUDCA?
Epitalon half-life is 0.5 hours; TUDCA half-life is 4 hours.
Can you stack Epitalon with TUDCA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper